Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Goodwill: 2009-2024

Historic Goodwill for UNITED THERAPEUTICS (UTHR) over the last 11 years, with Dec 2024 value amounting to $32.3 million.

  • UNITED THERAPEUTICS's Goodwill fell 4.15% to $32.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $32.3 million, marking a year-over-year decrease of 4.15%. This contributed to the annual value of $32.3 million for FY2024, which is 4.15% down from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Goodwill of $32.3 million as of Q4 2024, which was down 4.15% from $33.7 million recorded in Q4 2023.
  • In the past 5 years, UNITED THERAPEUTICS's Goodwill ranged from a high of $33.7 million in Q4 2023 and a low of $28.0 million during Q1 2020.
  • Moreover, its 3-year median value for Goodwill was $28.0 million (2022), whereas its average is $29.7 million.
  • Its Goodwill has fluctuated over the past 5 years, first dropped by 11.11% in 2020, then grew by 20.36% in 2023.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Goodwill stood at $28.0 million in 2020, then remained steady at $28.0 million in 2021, then remained steady at $28.0 million in 2022, then rose by 20.36% to $33.7 million in 2023, then declined by 4.15% to $32.3 million in 2024.
  • Its last three reported values are $32.3 million in Q4 2024, $33.7 million for Q4 2023, and $28.0 million during Q4 2022.